Stifel Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.3M | Sell |
1,823,288
-13,691
| -0.7% | -$123K | 0.02% | 675 |
|
|
2025
Q1 | $13.8M | Sell |
1,836,979
-6,007
| -0.3% | -$45.1K | 0.01% | 717 |
|
|
2024
Q4 | $13.9M | Sell |
1,842,986
-303
| -0% | -$2.28K | 0.01% | 722 |
|
|
2024
Q3 | $14M | Sell |
1,843,289
-363
| -0% | -$2.76K | 0.01% | 727 |
|
|
2024
Q2 | $11.4M | Sell |
1,843,652
-284
| -0% | -$1.76K | 0.01% | 766 |
|
|
2024
Q1 | $9.37M | Sell |
1,843,936
-119
| -0% | -$605 | 0.01% | 842 |
|
|
2023
Q4 | $11M | Buy |
1,844,055
+36
| +0% | +$216 | 0.01% | 740 |
|
|
2023
Q3 | $13.1M | Sell |
1,844,019
-535
| -0% | -$3.79K | 0.02% | 623 |
|
|
2023
Q2 | $13M | Buy |
1,844,554
+480
| +0% | +$3.38K | 0.02% | 618 |
|
|
2023
Q1 | $15.4M | Hold |
1,844,074
| – | – | 0.02% | 537 |
|
|
2022
Q4 | $21.2M | Sell |
1,844,074
-2,100
| -0.1% | -$24.1K | 0.03% | 435 |
|
|
2022
Q3 | $23.3M | Sell |
1,846,174
-3,850
| -0.2% | -$48.5K | 0.04% | 392 |
|
|
2022
Q2 | $19.6M | Sell |
1,850,024
-318
| -0% | -$3.36K | 0.03% | 457 |
|
|
2022
Q1 | $30.1M | Buy |
1,850,342
+818
| +0% | +$13.3K | 0.04% | 372 |
|
|
2021
Q4 | $25.6M | Sell |
1,849,524
-830
| -0% | -$11.5K | 0.03% | 426 |
|
|
2021
Q3 | $26.6M | Hold |
1,850,354
| – | – | 0.04% | 391 |
|
|
2021
Q2 | $29.3M | Hold |
1,850,354
| – | – | 0.04% | 345 |
|
|
2021
Q1 | $18.8M | Sell |
1,850,354
-191,745
| -9% | -$1.95M | 0.03% | 447 |
|
|
2020
Q4 | $15.2M | Hold |
2,042,099
| – | – | 0.03% | 476 |
|
|
2020
Q3 | $7.02M | Hold |
2,042,099
| – | – | 0.01% | 649 |
|
|
2020
Q2 | $9.73M | Sell |
2,042,099
-49,170
| -2% | -$234K | 0.02% | 513 |
|
|
2020
Q1 | $4.18M | Buy |
+2,091,269
| New | +$4.18M | 0.01% | 726 |
|